Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors
- 28 September 2011
- journal article
- research article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 39 (1), 23-34
- https://doi.org/10.1016/j.nucmedbio.2011.06.005
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1Journal of Neuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with 177Lu: in vitro comparison of acyclic and macrocyclic ligandsNuclear Medicine and Biology, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and DisappointmentsClinical Cancer Research, 2008
- A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsProceedings of the National Academy of Sciences, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteinsOncogene, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005